## **Core Concept**
The question tests the knowledge of β blockers used in the management of glaucoma, particularly in patients with hyperlipidemia. Glaucoma is a condition characterized by increased intraocular pressure (IOP) that can lead to optic nerve damage. β blockers are used to decrease IOP by reducing aqueous humor production. The concern with hyperlipidemia is that some β blockers can adversely affect lipid profiles.

## **Why the Correct Answer is Right**
The correct answer, **Carteolol**, is a β blocker that is specifically noted for its use in glaucoma patients with hyperlipidemia. Unlike some other β blockers, carteolol has a favorable effect on lipid profiles or is lipid-neutral, meaning it does not significantly worsen hyperlipidemia. It works by decreasing the production of aqueous humor, thereby reducing intraocular pressure.

## **Why Each Wrong Option is Incorrect**
- **Option A: Propranolol** is a non-selective β blocker with no particular advantage in terms of lipid profile; in fact, it can potentially worsen lipid profiles.
- **Option B: Timolol** is a commonly used β blocker in glaucoma but can have systemic effects, including effects on lipid profiles, though it's not the worst offender.
- **Option D: Betaxolol** is a β1 selective blocker used in glaucoma and is considered to have a more favorable systemic side effect profile, including less impact on lipid profiles compared to non-selective β blockers.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that when managing glaucoma, especially in patients with hyperlipidemia, the choice of β blocker can impact the patient's overall cardiovascular risk profile. **Carteolol** and **Betaxolol** are often considered in such cases due to their relatively favorable effects on lipids.

## **Correct Answer:** . Carteolol